Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product …
Over the last 12 months, insiders at Compass Therapeutics, Inc. have bought $0 and sold $0 worth of Compass Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Compass Therapeutics, Inc. have bought $19.83M and sold $103,708 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $33,700 was made by Schuetz Thomas J. (CHIEF EXECUTIVE OFFICER) on 2023‑03‑10.
2023-03-10 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 10,000 0.008% | $3.37 | $33,700 | -31.33% | ||
2023-02-27 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 20,000 0.016% | $3.98 | $79,600 | -39.44% | ||
2023-02-15 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 20,000 0.0153% | $3.86 | $77,200 | -38.69% | ||
2023-01-31 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 20,000 0.016% | $4.05 | $81,000 | -35.75% | ||
2023-01-24 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 20,000 0.0158% | $4.19 | $83,800 | -37.29% | ||
2022-11-25 | Sale | Bisker-Leib Vered | Chief Operating Officer | 2 <0.0001% | $4.36 | $9 | -28.83% | |
2022-11-23 | Sale | Bisker-Leib Vered | Chief Operating Officer | 9,569 0.0088% | $4.30 | $41,147 | -30.00% | |
2022-11-22 | Sale | Bisker-Leib Vered | Chief Operating Officer | 14,929 0.0139% | $4.19 | $62,553 | -27.27% | |
2022-11-08 | ORBIMED ADVISORS LLC | director | 402,000 0.2887% | $3.21 | $1.29M | -25.18% | ||
2022-11-08 | GORDON CARL L | director | 402,000 0.2887% | $3.21 | $1.29M | -25.18% | ||
2022-09-07 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 15,000 0.0148% | $3.03 | $45,450 | +4.92% | ||
2022-09-01 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 15,000 0.0145% | $2.83 | $42,450 | +10.34% | ||
2022-08-17 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 15,000 0.0151% | $3.05 | $45,750 | +6.67% | ||
2022-08-10 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 15,000 0.0146% | $2.64 | $39,600 | +19.40% | ||
2022-08-01 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 15,000 0.0145% | $2.58 | $38,700 | +21.21% | ||
2022-06-21 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 20,000 0.019% | $2.80 | $56,000 | +9.25% | ||
2022-06-16 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 20,000 0.0188% | $2.34 | $46,800 | +28.74% | ||
2022-06-13 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 30,000 0.0339% | $2.29 | $68,700 | +57.71% | ||
2022-06-06 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 30,000 0.0304% | $2.83 | $84,900 | +14.08% | ||
2022-06-01 | Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 20,000 0.0206% | $3.03 | $60,600 | +8.22% |
ORBIMED ADVISORS LLC | director | 15219994 11.0064% | $37.44M | 3 | 0 | <0.0001% |
GORDON CARL L | director | 15219994 11.0064% | $37.44M | 5 | 0 | +26.53% |
OrbiMed Genesis GP LLC | 14690178 10.6233% | $36.14M | 2 | 0 | +76.65% | |
Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | 6021873 4.3547% | $14.81M | 20 | 0 | +7.17% |
Sunderland Julie | director | 2502025 1.8094% | $6.15M | 1 | 0 |
$99,438,720 | 81 | 6.74% | $290.44M | |
$5,911,307 | 70 | -1.38% | $309.77M | |
$109,415,500 | 33 | 18.13% | $353.41M | |
Compass Therapeutics, Inc. (CMPX) | $41,446,394 | 27 | 12.91% | $340.18M |
$24,857,912 | 21 | -35.40% | $287.11M |
Increased Positions | 55 | +84.62% | 17M | +18.36% |
Decreased Positions | 23 | -35.38% | 8M | -8.48% |
New Positions | 19 | New | 8M | New |
Sold Out Positions | 7 | Sold Out | 2M | Sold Out |
Total Postitions | 97 | +49.23% | 101M | +9.88% |
Orbimed Advisors Llc | $64,852.00 | 16.2% | 22.36M | 0 | 0% | 2024-12-31 |
Blackstone Inc. | $29,073.00 | 7.27% | 10.03M | 0 | 0% | 2024-12-31 |
Mpm Bioimpact Llc | $24,847.00 | 6.21% | 8.57M | +3M | +51.86% | 2024-12-31 |
Enavate Sciences Gp, Llc | $22,586.00 | 5.64% | 7.79M | +8M | New | 2024-12-31 |
Blackrock, Inc. | $19,974.00 | 4.99% | 6.89M | +67,163 | +0.98% | 2024-12-31 |
Adage Capital Partners Gp, L.L.C. | $17,385.00 | 4.34% | 5.99M | -5M | -46.14% | 2024-12-31 |
Tang Capital Management Llc | $17,110.00 | 4.28% | 5.9M | +4M | +225.43% | 2024-12-31 |
Rock Springs Capital Management Lp | $16,761.00 | 4.19% | 5.78M | +150,336 | +2.67% | 2024-12-31 |
Vanguard Group Inc | $13,683.00 | 3.42% | 4.72M | +435,008 | +10.16% | 2024-12-31 |
Fmr Llc | $11,996.00 | 3% | 4.14M | +130 | +<0.01% | 2024-12-31 |